Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here: https://rb.gy/09bxx

Press releases

December 9, 2016 | REGULATORY

Summary from the extraordinary general meeting of Immunovia

Read press release
December 9, 2016 | REGULATORY

Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Read press release
December 9, 2016 | REGULATORY

Immunovia announces collaboration with the renowned Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid

Read press release
November 18, 2016 | REGULATORY

Immunovia awarded 2016 Stars of Innovation Prize

Read press release
November 16, 2016 | REGULATORY

KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)

Read press release
November 15, 2016

WORLD PANCREATIC CANCER DAY, LUND SWEDEN, November 17, 2016 – It’s About Time

Read press release
October 19, 2016 | REGULATORY

Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

Read press release
October 13, 2016 | REGULATORY

Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016

Read press release
October 7, 2016 | REGULATORY

Immunovia: Insiders transfer subscription rights free of charge

Read press release
September 26, 2016 | REGULATORY

Immunovia publishes prospectus regarding preferential rights issue

Read press release
September 15, 2016 | REGULATORY

The board of directors of Immunovia resolves on a directed and preferential right issue

Read press release
September 14, 2016 | REGULATORY

Immunovia intends to launch a directed and preferential right issue

Read press release
1 23 24 25 26 27 28